Novartis announced positive results from two Phase 3 studies evaluating ianalumab, a B-cell-depleting antibody targeting BAFF-R, in Sjögren’s syndrome. Both trials met their primary endpoints, demonstrating statistically significant improvements in disease activity at 52 weeks compared to placebo. The drug exhibited a favorable safety profile. These first-ever global late-stage successes for Sjögren’s disease mark a milestone for targeted autoimmune therapies, with Novartis preparing regulatory filings.